Early diagnostic protein biomarkers for breast cancer: how far have we come?
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
Molecular insights on basal-like breast cancer
Fingolimod potentiates the effects of sunitinib malate in a rat breast cancer model
Integration of BRCA1-mediated miRNA and mRNA profiles reveals microRNA regulation of TRAF2 and NFκB pathway
A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines
T cells sensitized with breast tumor progenitor cell vaccine have therapeutic activity against spontaneous HER2/ neu tumors
Psoriasin (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation
Biologically effective dose and breast cancer conservative treatment: is duration of radiation therapy really important?
Antitumor effects of cytoplasmic delivery of an innate adjuvant receptor ligand, poly(I:C), on human breast cancer
SLC22A5/OCTN2 expression in breast cancer is induced by estrogen via a novel intronic estrogen-response element (ERE)
Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin
Methylation of O 6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients
Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells
Stromal-epithelial interactions modulate cross-talk between prolactin receptor and HER2/Neu in breast cancer
Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients
Autologous microsurgical breast reconstruction and coronary artery bypass grafting: an anatomical study and clinical implications
Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy
The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer
MUTYH gene variants and breast cancer in a Dutch case-control study
14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers
Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer
Aromatase inhibitors and calcium absorption in early stage breast cancer
An abnormal screening mammogram causes more anxiety than a palpable lump in benign breast disease
The fibroblast growth factor receptor 1 (FGFR1), a marker of response to chemoradiotherapy in breast cancer?
Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study
High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study
Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene
A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer
Predictors of functional shoulder recovery at 1 and 12 months after breast cancer surgery
Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers
A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103)
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study
Breast cancer incidence trends in European women aged 20-39 years at diagnosis
Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer
Quality of life over time in women diagnosed with ductal carcinoma in situ, early-stage invasive breast cancer, and age-matched controls
Genetic polymorphisms in telomere pathway genes, telomere length, and breast cancer survival
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel
Clinical and pathologic characteristics of BRCA -positive and BRCA -negative male breast cancer patients: results from a collaborative multicenter study in Italy
Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL)
Predisposition gene identification in common cancers by exome sequencing: insights from familial breast cancer
Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat
Comments on the use of a single or multiple probeset approach for microarray-based analyses of routine molecular markers in breast cancer
Erratum to: Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents